兴齐眼药表示，报告期内，公司坚持自主研发，巩固核心竞争优势，加大市场拓展力度，持续优化产品 结构，深化成本费用管控，推动整体盈利能力提升，公司营业收入及净利润均保持稳定增长，经营业绩 延续良好增长态势。 北京商报讯（记者 丁宁）1月22日晚间，兴齐眼药（300573）发布2025年度业绩预告显示，预计2025年 归属净利润6.62亿元—7.49亿元，同比增长95.82%—121.56%。 ...

兴齐眼药公告，预计2025年度归属于上市公司股东的净利润为6.62亿元-7.49亿元，比上年同期增长 95.82%-121.56%。报告期内，公司坚持自主研发，巩固核心竞争优势，加大市场拓展力度，持续优化产 品结构，深化成本费用管控，推动整体盈利能力提升，经营业绩延续良好增长态势。 (本文来自第一财经) ...

人民财讯1月22日电，兴齐眼药（300573）1月22日发布业绩预告，预计2025年归母净利润6.62亿元— 7.49亿元，同比增长95.82%—121.56%。报告期内，公司坚持自主研发，加大市场拓展力度，持续优化 产品结构，深化成本费用管控，推动整体盈利能力提升，公司营业收入及净利润均保持稳定增长，经营 业绩延续良好增长态势。 ...

Core Viewpoint - The article discusses the increasing prevalence of "modern diseases" such as myopia, smartphone addiction, and hypertension, and highlights how technology is being leveraged by Japanese companies to combat these issues. Group 1 - The development of eyewear devices aimed at controlling the progression of myopia is advancing. Myopia is identified as a typical modern disease, as emphasized by the CEO of Kubota Pharmaceutical Holdings [6]. - Technologies aimed at overcoming smartphone addiction are emerging, including the use of NFC tags to prevent excessive use of social media [7]. - Digital therapies through apps for treating diseases like hypertension are gaining attention [7].

Group 1 - The core point of the article is that Xingqi Eye Medicine announced its cash dividend distribution plan for the first half of 2025, which is 7.00 yuan per 10 shares (including tax) [1] - The record date for the dividend distribution is set for September 23, 2025 [1] - The ex-dividend date is scheduled for September 24, 2025 [1]